TABLE 3.

Overall multivariable linear regression model

Covariate	Coefficient	P
Age at diagnosis (years)	0.02	0.74
Education
College degree vs high school	1.04	0.49
High school degree vs high school	1.45	0.36
College vs high school	−0.22	0.9
Race/ethnicity
African American vs Caucasian	−4.36	0.07
Asian/Pacific Islander vs Caucasian	−4.39	0.33
Latino vs Caucasian	−4.77	0.2
Other/unknown vs Caucasian	0.83	0.81
Married/partnered (yes vs no)	−0.99	0.53
PSA level at diagnosis (ng/mL)	0.03	0.52
Biopsy Gleason grade
7 (3+4) vs 2–6	−1.03	0.38
7 (4+3) vs 2–6	1.29	0.45
8–10 vs 2–6	1.96	0.32
Clinical T-stage
cT2 vs cT1	−0.27	0.76
cT3 vs cT1	2.76	0.64
Primary treatment
PADT vs RP	−2.47	0.27
RT vs RP	−0.58	0.65
Any neoadjuvant/adjuvant treatment	−1.28	0.33
Time from diagnosis to treatment (months)	0.1	0.75
Baseline body mass index	0.01	0.95
Baseline number of comorbidities	−0.73	0.04
Baseline SF-36 MCS	0.14	< 0.01
Baseline SF-36 PCS	0.13	0.02
Baseline fear of cancer recurrence	−0.16	< 0.01
PCI sexual function decline	−1.81	0.04
PCI bowel function decline	−2.84	< 0.01
PCI urinary function decline	−2.15	0.02

MCS, Mental Component Summary; PADT, primary androgen deprivation therapy; PCI, Prostate Cancer Index; PCS, Physical Component Summary; RP, radical prostatectomy; RT, radiation therapy; SF-36, 36-item short-form health survey.